Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Chemotherapy-Induced Nausea and Vomiting: Cannabinoids01:21

Chemotherapy-Induced Nausea and Vomiting: Cannabinoids

706
Tetrahydrocannabinol (THC) is a phytocannabinoid that primarily interacts with the CB1 receptor, a type of G protein-coupled receptor (GPCR) predominantly in and around the chemoreceptor trigger zone (CTZ) and emetic center. THC also blocks the serotonin receptor activity in the dorsal vagal complex (DVC) by inhibiting serotonin release. THC exerts its anti-emetic effects through these interactions, which are beneficial for patients undergoing chemotherapy.
Two synthetic agonists of THC,...
706
Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists01:29

Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists

822
Dopamine receptor antagonists, also known as antipsychotic agents, are critical in managing chemotherapy-induced vomiting. These antiemetic agents block dopamine receptors in the chemoreceptor trigger zone (CTZ), inhibiting signal transmission to the vomiting center. Antipsychotic agents encompass phenothiazines (PTZ), butyrophenones, benzamides, and thienobenzodiazepines (Zyprexa), which are utilized for their antiemetic and sedative properties.
Phenothiazines, such as prochlorperazine...
822
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists01:27

Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists

608
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
608
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

601
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates...
601
Peripheral Arterial Disease II: Clinical Manifestations and Diagnostic Evaluation01:21

Peripheral Arterial Disease II: Clinical Manifestations and Diagnostic Evaluation

367
Clinical manifestationsPeripheral Arterial Disease (PAD) manifests through a range of symptoms, from the characteristic intermittent claudication to atypical presentations and severe complications in advanced stages. Intermittent claudication, a hallmark symptom of PAD, presents as exercise-induced muscle pain that typically resolves within minutes of rest. This pain is reproducible and stems from inadequate blood flow, leading to the accumulation of lactic acid produced during anaerobic...
367
Optimal Foraging00:48

Optimal Foraging

13.7K
How animals obtain and eat their food is called foraging behavior. Foraging can include searching for plants and hunting for prey and depends on the species and environment.
13.7K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Australian clinical practice guideline: diagnosis and treatment of idiopathic multicentric Castleman disease.

Internal medicine journal·2026
Same author

Efficacy and Tolerability of Weekly Bortezomib, Lenalidomide, and Dexamethasone Protocols in Transplant-Ineligible Newly Diagnosed Myeloma: An Australian Real-World, Multicenter Study.

Asia-Pacific journal of clinical oncology·2026
Same author

Early de-escalation of broad-spectrum antibiotic therapy in febrile neutropenia.

Internal medicine journal·2026
Same author

Author Correction: Exome analysis links kidney malformations to developmental disorders and reveals causal genes.

Nature communications·2025
Same author

Practice Patterns in Management of Low- to Intermediate-Grade Salivary Gland Carcinoma: A Multi-Institutional Study.

Laryngoscope investigative otolaryngology·2025
Same author

Risk factors and survival impact of severe radiation-related late toxicities in head and neck cancer-a cohort study.

Lancet regional health. Americas·2025

Related Experiment Video

Updated: Jan 21, 2026

Corneal Confocal Microscopy: A Novel Non-invasive Technique to Quantify Small Fibre Pathology in Peripheral Neuropathies
11:29

Corneal Confocal Microscopy: A Novel Non-invasive Technique to Quantify Small Fibre Pathology in Peripheral Neuropathies

Published on: January 3, 2011

27.3K

Optimizing Clinical Screening for Chemotherapy-Induced Peripheral Neuropathy.

J Matt McCrary1, David Goldstein2, Terry Trinh1

  • 1Prince of Wales Clinical School, University of New South Wales, Kensington, Australia.

Journal of Pain and Symptom Management
|August 3, 2019
PubMed
Summary

Patient-reported outcome (PRO) screening tools effectively identify chemotherapy-induced peripheral neuropathy (CIPN) while avoiding biases of clinician-rated tools. However, screening tools may misidentify up to 23% of patients, highlighting the need for comprehensive evaluations.

Keywords:
Neurotoxicitycancer survivorshipchemotherapyquality of life

More Related Videos

Rat Model of Photochemically-Induced Posterior Ischemic Optic Neuropathy
14:54

Rat Model of Photochemically-Induced Posterior Ischemic Optic Neuropathy

Published on: November 29, 2015

9.0K
Nerve Ultrasound Protocol to Detect Dysimmune Neuropathies
08:56

Nerve Ultrasound Protocol to Detect Dysimmune Neuropathies

Published on: October 7, 2021

3.3K

Related Experiment Videos

Last Updated: Jan 21, 2026

Corneal Confocal Microscopy: A Novel Non-invasive Technique to Quantify Small Fibre Pathology in Peripheral Neuropathies
11:29

Corneal Confocal Microscopy: A Novel Non-invasive Technique to Quantify Small Fibre Pathology in Peripheral Neuropathies

Published on: January 3, 2011

27.3K
Rat Model of Photochemically-Induced Posterior Ischemic Optic Neuropathy
14:54

Rat Model of Photochemically-Induced Posterior Ischemic Optic Neuropathy

Published on: November 29, 2015

9.0K
Nerve Ultrasound Protocol to Detect Dysimmune Neuropathies
08:56

Nerve Ultrasound Protocol to Detect Dysimmune Neuropathies

Published on: October 7, 2021

3.3K

Area of Science:

  • Oncology
  • Neuroscience
  • Clinical Trials

Background:

  • Accurate screening for treatment-related toxicities, such as chemotherapy-induced peripheral neuropathy (CIPN), is crucial for patient management.
  • Existing screening tools for CIPN have demonstrated limitations, prompting the development of alternative methods.

Purpose of the Study:

  • To evaluate the relative construct validity and discriminant properties of available CIPN screening tools.
  • To compare clinician-rated and patient-reported outcome (PRO) screening tools for CIPN detection.

Main Methods:

  • 316 patients undergoing potentially neurotoxic therapies were assessed using various CIPN screening tools and comprehensive evaluations.
  • Assessments included clinician-rated (e.g., NCI-CTCAE) and PRO (e.g., PRO-CTCAE) tools, alongside comprehensive clinician-rated (Total Neuropathy Score) and PRO (FACT-G/QOL) measures.
  • 644 total testing sessions were conducted across one or multiple timepoints per patient.

Main Results:

  • Moderate-to-high correlations (rho: 0.55-0.75) were observed between screening tools and comprehensive CIPN assessments.
  • Screening tools demonstrated similar discriminant properties, with predicted accuracy of 77%-91% in identifying clinically significant CIPN (grade 2/3).
  • PRO screening tools showed adequate performance without the biases associated with clinician-rated tools.

Conclusions:

  • PRO screening tools offer a viable option for CIPN screening, mitigating biases inherent in clinician-rated assessments.
  • The addition of brief objective tests did not enhance the value of PRO screening.
  • A significant proportion of patients (up to 23%) may be misidentified by screening tools, underscoring the necessity of comprehensive CIPN evaluations for high-risk individuals.